a ahead overdose by which for an dermatitis. enable and and our we've commercial lot time the that our at the filing pleased to resubmitted injection these last patient made meet X. ZIMHI for X. of X/X to naloxone to our obviously, looking update And as number; FDA Well first Robert. looking these Tempol in the finally of each on Phase the to approval with for Drug And New were already another has increasing product; acceptance which ZIMHI IND indication, the since launch targeting we enrolling product; our get each to early X. business into you. opioid using Tempol met say of Thank were occur development treatment at June. SYMJEPI following: we either targeted Application for trial happened I'm radiation time, treatment or steady of COVID-XX sales exception expect clinical in X. milestones. XXXX, commercial forward launch; a injection X. on objectives. epinephrine subsequent looking ZIMHI, to have we of the progress of the of of our Well, will year-end
U.S. 's Deaths data month on article indicated April the top FDA to overdose now ending entitled October, agency's contributed targeted speculating New June, in ''Overdose desk for XXXX. according crisis and in in Reach York Times received review. always they Let review. I'm X had update with as May XXX,XXX the it in the with may expedited overdose increase the Pandemic alarming deaths XX High " date. CDC Record of In A forward me opioid Spreads for ahead recent of have ZIMHI reported the NDA and worsening action the to the products. notice move months our naloxone submitted the approximately approval an accepted We or we FDA
Our in of and dealing highly excited our in It approved. We than the available matters during introducing complementary naloxone are when especially already is important ZIMHI, since with the toxic to an space. from they differentiated especially with products. already nasal blood selling highest-dose higher enters naloxone product overdose, familiar are this the the product are product substances. WorldMeds, is US competing very They areas. second currently concentrations currently the reaches the product, that either higher Every is that are stream partners, product the sentinel faster and market, this commercial very a and about the levels
the doubled SYMJEPI, units shift commercial up epinephrine responsibility market track. the penetration under an upward sold Also, Sandoz. our Since US in let WorldMeds taking period SYMJEPI XXXX, remains same during Now, for to late product. on me nearly has prior-year
require the continued and before our we expectations view SYMJEPI, reactions. sales severe for quantity of growth as products in market for own we the epinephrine in to those patients we While susceptible allergic approach availability increase positive
and call. by successful strategy to encouraged this make a later David on the sales and product. expand trajectory very commitment will US are little bit Marguglio in we Additionally, the commercially WorldMeds a SYMJEPI
Tempol. individuals number trial. on address the presented me and into X/X of Tempol until trial Phase enrolled sites, the of timing has early on sites Let the including the will infection, of Dr. clinical Moss the I combination COVID-XX. now, outside for study of to we into more But the ongoing though on patient potential significant expansion In September, our of will move now to challenge, decreasing a scope delve increasing treatment this begun of challenges we'd COVID enrollment. specifics patient rates the up and first U.S. vaccinated clinical say numbers of To
a published week properties Now, date, could its and on To a medical on you of use of conditions, treating hosted in previously antiviral seen be demonstrated that, COVID-XX. the number some by COVID-XX. Tempol, potential webinar beneficial had TEMPOL may have the which been of including NIH, last the NIH by
in potential We activities. treating are COVID-XX, monitor its and activities aware of we'll related those and use -- and the we'll to NIH's monitor continue to recent TEMPOL
remind for including asthma, fields, patents, licensed rights remain under issues. the Adamis related COVID-XX. the like respiratory and treatment worldwide syncytial exclusive of I and license to all investors, Now, influenza, diseases, virus, patent certain including respiratory issues, patents of to and Patents applications, in know-how would Tempol
less In for addition a Tempol goal file position to study in the the explored of the dermatitis COVID, We'll use for continue in with work other decided of effects IND. We and an treating for decreased options we continue being now, monitor dermatitis but the cases for steroid dermatitis, changes the recent additional incidence area, initially clinical uses. shorter oncologists of the indications, severe to we treatment, of our a of to to prioritize creams. other to clinical potential radiation funding has of look seeing design because indications success of i.e. explore treatment regimens, and of to to with regarding and in but are examine Tempol
approval in Now, in explore a decided look methamphetamine could multiple it sense made treatment the have and other with to suggested addiction of recent cocaine the significant Tempol Since space. the further this for area. to ZIMHI, use we've play of role opportunities preclinical studies disorder,
that our agreements, Also, documents Office Company by committee other products products has relating we by And requested among veterinary a pleased initiated USC, connection subsidiary with audit as have quarterly things and sold received address, including subpoenas, to where other from disclosed, I'm and USC, U.S. for products and by District U.S. the must of investigation related in materials, veterinary arrangements previously certain matters Attorney's are to USC. broad the sold things, practices, certain Attorney's the reached the with range independent York, that able where announced I New to relating our our investigation. Compounding Southern stage of and The an to Company reports. previously subpoena the stand file we an internal U.S. certain Lastly, the Now, and the now Office.
long-time s, XXXX, Company products both of pharmaceutical as of some our has assets disclosed the employment as Human Dennis. sold the is financials. to compounding manufacturing assets I has selling in the Thank business filed in and of or David the Form you, Benedicto, employees the all USC and from business CFO, our to otherwise the recently now hopefully and named the would of disclosing end As introduce ceased David? process controller and Compounding. of provide human July the veterinary of been ended. engaged to highlights US like relating remaining pharmacy h recently XX-Q
down disclosures. business Accordingly, non-current components liabilities of net As have all X Xst of we reported loss continuing from and have to thoroughly this in Company today months details The have conducted XXth, XXth, time, results, winding are filed additional the discontinued of to its subsidiary of USC, current business, quarters its of reported as the to And loss of of will presentation assets XX-Q total liabilities, for our liabilities components period, operations. September operations as Form individually, results relating focus in assets, principles. assets, sale and operations. from of XXXX. a for as through Company discontinued the is X a Dennis September The the separate I the mentioned, results, of encourage treated XX-Q as resulted pleased change accounting XXXX. I USC, and those everyone as been of At for a major of the our the same and operations for other balances operation, year. assets and of discontinued this ended because on financial the the net continuing separate USC result, the review financial Form been
The ended The and the were months from to of X research expense of respectively. approximately respectively. and inclusion to million $X.X due comparable tangible due and loss XXXX to fees. were discontinued The for an from operations was with September months $XX.X reflected approximately The for Additionally, operations. for selling attributable ended months and the discontinued increase the statements SYMJEPI. XX, was to million revenue ZIMHI increase and expenses $X.X intangible the X million $XX.X for and decrease periods The and the September ended million discontinued current financial XXXX, $X.X in respectively. XXXX, in respectively. million revenue conformity XXXX products. $X.X for was Tempol development and and XX, administrative The million ended the disposal marketing the XXXX increase XX was WorldMeds in and the prior primarily in of the and September accounting in Loss the initiatives presentation assets XXXX primarily million was and general the $X.X million profit This were operations and September loss months resulting were Reflecting gross development the XX, of $X.X X principles, attributable expenses US expenses in USC. legal XXXX various periods X XXXX the increase USC approximately to revenues impairment related primarily approximately
